{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T08:23:56Z","timestamp":1766305436701,"version":"3.40.5"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NOMA"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.humimm.2016.04.001","type":"journal-article","created":{"date-parts":[[2016,4,8]],"date-time":"2016-04-08T12:07:14Z","timestamp":1460117234000},"page":"429-431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A study of HLA-B\u221715:02 in a Sri Lankan population: Implications for pharmacogenomic testing"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3890-5123","authenticated-orcid":false,"given":"K.M.D.","family":"Gunathilake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.T.","family":"Wettasinghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.H.W.","family":"Dissanayake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humimm.2016.04.001_b0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7439\/ijbr.v4i9.305","article-title":"Anti-epileptic drugs and severe cutaneous drug reactions in certain ethnic populations & HLA association","volume":"4","author":"Ahmad","year":"2013","journal-title":"Int. J. Biomed. Res."},{"key":"10.1016\/j.humimm.2016.04.001_b0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/01.all.0000173785.81024.33","article-title":"Epidemiology of hypersensitivity drug reactions","volume":"5","author":"Gomes","year":"2005","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.humimm.2016.04.001_b0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","article-title":"A marker for Stevens-Johnson syndrome: ethnicity matters","volume":"6","author":"Lonjou","year":"2006","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.humimm.2016.04.001_b0020","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.seizure.2011.02.003","article-title":"Association between HLA-B\u22171502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland","volume":"20","author":"Wang","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.humimm.2016.04.001_b0025","first-page":"15","article-title":"Association of HLA-B\u22171502 allele and carbamazepine induced severe adverse cutaneous drug reaction among Asians, a review","volume":"13","author":"Lim","year":"2008","journal-title":"Neurol. Asia"},{"key":"10.1016\/j.humimm.2016.04.001_b0030","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B\u22171502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.humimm.2016.04.001_b0035","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with the HLAB\u22171502 allele in Thai population","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.humimm.2016.04.001_b0040","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2217\/14622416.7.6.813","article-title":"HLA-B locus in Caucasian patients with carbamazepine hypersensitivity","volume":"7","author":"Alfirevic","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.humimm.2016.04.001_b0045","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.humimm.2016.04.001_b0050","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1535-7511.2008.00263.x","article-title":"Of race, ethnicity, and rash: the genetics of antiepileptic drug-induced skin reactions","volume":"8","author":"Miller","year":"2008","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.humimm.2016.04.001_b0055","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","article-title":"Carbamazepine, HLA-B\u22171502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations","volume":"9","author":"FerrellJr","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.humimm.2016.04.001_b0060","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B\u22171502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.humimm.2016.04.001_b0065","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1399-0039.1995.tb03127.x","article-title":"Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB5 & DQBl by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP)","volume":"46","author":"Bunce","year":"1995","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.humimm.2016.04.001_b0070","unstructured":"Sri Lanka Demographics Profile 2014. Index Mundi. In; <http:\/\/www.indexmundi.com\/sri_lanka\/demographics_profile.html> (Accessed on 09.11.2015)."},{"key":"10.1016\/j.humimm.2016.04.001_b0075","first-page":"707","article-title":"Genetic variation in Sri Lanka","volume":"68","author":"Papiha","year":"1996","journal-title":"Hum. Biol."},{"key":"10.1016\/j.humimm.2016.04.001_b0080","unstructured":"Futch T, Needham D. Carbamazepine Sensitivity (HLA-B\u22171502). In; <http:\/\/elcaminogmi.dnadirect.com\/grc\/physician-site\/hlab-carbamazepine-response\/carbamazepine-sensitivity-hla-b1502.html>. 2011 (Accessed on 20.08.2014)."},{"key":"10.1016\/j.humimm.2016.04.001_b0085","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1346-8138.2010.01196.x","article-title":"Pharmacogenomics of cutaneous adverse drug reactions","volume":"38","author":"Aihara","year":"2011","journal-title":"J. Dermatol."},{"key":"10.1016\/j.humimm.2016.04.001_b0090","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.humimm.2004.08.051","article-title":"HLA-A, -B and -Cw allele frequencies in a Pawra population from Khandesh, India","volume":"65","author":"Shankarkumar","year":"2004","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.humimm.2016.04.001_b0095","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.humimm.2004.08.057","article-title":"HLA-A, -B and -Cw allele frequencies in a Bhil population from Western India","volume":"65","author":"Shankarkumar","year":"2004","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.humimm.2016.04.001_b0100","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.humimm.2004.08.056","article-title":"HLA-A, -B, -Cw, -DQA1, -DQB1 and -DRB1 alleles and KIR alleles in a hindu population from Punjab, India","volume":"65","author":"Rajalingam","year":"2004","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.humimm.2016.04.001_b0105","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.humimm.2004.08.069","article-title":"HLA-A, -B and -Cw allele frequencies in a Parsi population from Western India","volume":"65","author":"Shankarkumar","year":"2004","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.humimm.2016.04.001_b0110","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.humimm.2004.08.055","article-title":"HLA-A, -B and -Cw allele frequencies in a Nadar population from Tamil Nadu, India","volume":"65","author":"Shankarkumar","year":"2004","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.humimm.2016.04.001_b0115","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4103\/0378-6323.57718","article-title":"Association of HLA-B\u22171502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians","volume":"75","author":"Mehta","year":"2009","journal-title":"Ind. J. Dermatol. Venereol. Leprol."},{"key":"10.1016\/j.humimm.2016.04.001_b0120","unstructured":"FDA Alert [12\/12\/2007]. Dangerous or even fatal skin reactions \u2013 Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics) \u2013 Healthcare Professional Sheet text version. In; <http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124718.htm> (Accessed on 22.08.2014)."},{"key":"10.1016\/j.humimm.2016.04.001_b0125","unstructured":"FDA Alert [11\/24\/08].Information for Healthcare Professionals: Phenytoin (marketed as Dilantin, Phenytek and generics) and Fosphenytoin Sodium (marketed as Cerebyx and generics). In; <http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124788.htm> (Accessed on 09.11.2015)."},{"key":"10.1016\/j.humimm.2016.04.001_b0130","first-page":"9","article-title":"Practical issues in calculating the sample size for prevalence studies","volume":"1","author":"Naing","year":"2006","journal-title":"Arch. Orofac. Sci."}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885916300416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885916300416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T06:40:16Z","timestamp":1567752016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885916300416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0198885916300416"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2016.04.001","relation":{},"ISSN":["0198-8859"],"issn-type":[{"type":"print","value":"0198-8859"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A study of HLA-B\u221715:02 in a Sri Lankan population: Implications for pharmacogenomic testing","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2016.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}